A shift in mindset : the FDA removes the Black Box Warning for Menopausal Hormone Therapy!

Historic news for women’s health!

The U.S. Food and Drug Administration (FDA) has announced that it will remove the “black box” safety warning from most menopausal hormone therapies.

A turning point after more than 20 years of confusion and fear.

As Dr. Marty Makary, FDA Commissioner, stated:

“We are stopping the fear machine steering women away from this life-changing, even life-saving treatment.”

What is changing?

The “black box” warning, the most severe caution a medication can carry, has been present since 2003.

It warned of increased risks of cardiovascular disease, stroke, breast cancer, and dementia associated with hormone therapy.

Now, the FDA recognizes that the data supporting those risks were largely based on older women starting treatment years after menopause.

The science has evolved.

Newer analyses show that when hormone therapy is started before age 60 or within 10 years of menopause, it is generally safe and provides significant benefits for cardiovascular, bone, and brain health, as well as quality of life.

Why this change matters

For decades, fear and misinformation led to a dramatic drop in prescriptions, from 1 in 4 women using hormones in the 1990s to only 1 in 25 by 2020.

Millions of women were left untreated for symptoms that can deeply affect daily life and long-term health.

A shift toward individualized care

The FDA emphasizes that hormone therapy decisions should now be guided by personalized evaluation:

+ The patient’s age and time since menopause.

+ The type of hormone and route of administration (systemic or local).

+ Individual risk factors such as prior breast cancer or thrombotic risk.

A victory for evidence-based medicine

This decision reflects the consensus of numerous experts who have advocated for years to align labeling with the latest science.

Hormone therapy, when prescribed appropriately, takes its place as a pillar of women’s midlife health and longevity.

For health professionals

This is the moment to re-evaluate your approach:

+ Revisit the latest evidence on hormone therapy initiation timing.

+ Discuss benefits and risks openly with patients, without fear-based bias.

Empowering women with accurate, up-to-date information starts with informed practitioners.